Study guide
12.3 Neonatal Hyperbilirubinemia, Bilirubin Metabolism & Phototherapy Protocols
NCC Inpatient Obstetric Nursing RNC-OB
Track your progress as you read
Finished sections get a check mark.
1 Chapter 0: Introduction & How to Use This Guide
0.1 About the RNC-OB Credential & Exam Blueprint 0.2 How to Use This Study Guide & Clinical Learning Methodology
2 Chapter 1: Pregnancy Complications — Maternal Medical Conditions
1.1 Hypertensive Disorders of Pregnancy 1.2 HELLP Syndrome & Hepatic Disorders of Pregnancy 1.3 Diabetes Mellitus in Pregnancy 1.4 Maternal Cardiac and Respiratory Disorders 1.5 Infectious Diseases in Inpatient Obstetrics 1.6 Hematologic, Endocrine, Connective Tissue & Other Systemic Disorders
3 Chapter 2: Pregnancy Complications — Preterm Labor, Multiple Gestation, Placental & Fetal Disorders
2.1 Psychosocial Disorders, Substance Use & Environmental Exposures 2.2 Preterm Labor: Assessment, Tocolysis & Neuroprotection 2.3 Multiple Gestation: Placentation, Chorionicity & Complications 2.4 Placental Disorders: Previa, Abruption, Vasa Previa & PAS 2.5 Fetal Growth Disorders & Amniotic Fluid Complications
4 Chapter 3: Antenatal Fetal Assessment & Surveillance
3.1 Antenatal Testing Methods & Indications for Fetal Surveillance 3.2 Nonstress Test (NST), Contraction Stress Test (CST) & Biophysical Profile (BPP) 3.3 Diagnostic Prenatal Procedures (Amniocentesis, CVS, PUBS, cfDNA & Ultrasound) 3.4 Fetal Oxygenation Physiology & Acid-Base Regulation 3.5 Umbilical Cord Blood Gas Collection & Clinical Interpretation
5 Chapter 4: Fetal Assessment & Electronic Fetal Monitoring (EFM)
4.1 NICHD Electronic Fetal Monitoring Terminology & Baseline Features 4.2 FHR Decelerations, Acceleration Patterns & Uterine Activity 4.3 The NICHD Three-Tier Fetal Heart Rate Classification System 4.4 Intrauterine Resuscitation & Clinical Action Protocols 4.5 Fetal Arrhythmias, Dysrhythmias & Artifact Differentiation
6 Chapter 5: Labor & Birth Physiology — Mechanics, Cardinal Movements, Stages & Support
5.1 Physiology of Labor & Uterine Mechanics 5.2 Pelvic Anatomy, Fetal Lie, Presentation & Cardinal Movements of Labor 5.3 Stages of Labor, Cervical Dilatation Dynamics & Progression Guidelines 5.4 Intrapartum Admission Assessment, Obstetric Triage & Membrane Rupture Evaluation 5.5 Labor Support, Non-Pharmacologic Pain Management & Physiologic Birth Practices
7 Chapter 6: Labor & Birth Interventions — Cervical Ripening, Induction, Pain Management & Anesthesia
6.1 Bishop Scoring, Pre-Induction Cervical Ripening & Mechanical Methods 6.2 Oxytocin Administration, Titration Protocols & Uterine Tachysystole Management 6.3 Nonpharmacologic Comfort & Labor Pain Management Strategies 6.4 Systemic Opioid Analgesia & Inhaled Nitrous Oxide 6.5 Neuraxial Analgesia, Spinal/Epidural Complications & General Anesthesia
8 Chapter 7: Labor & Birth — Operative Deliveries, TOLAC/VBAC & Special Intrapartum Procedures
7.1 External Cephalic Version (ECV) & Malpresentation Management 7.2 Operative Vaginal Delivery: Vacuum Extraction & Forceps-Assisted Birth 7.3 Cesarean Delivery: Surgical Indications, Intraoperative Management & PACU Recovery 7.4 Trial of Labor After Cesarean (TOLAC) & Vaginal Birth After Cesarean (VBAC) 7.5 Special Intrapartum Procedures: Amniotomy, Amnioinfusion, Cervical Ripening & Labor Augmentation
9 Chapter 8: Obstetric Emergencies & Critical Care
8.1 Shoulder Dystocia Management & HELPERR Protocol 8.2 Umbilical Cord Prolapse & Feto-Vascular Emergencies 8.3 Uterine Rupture & Acute Uterine Inversion 8.4 Amniotic Fluid Embolism (Anaphylactoid Syndrome of Pregnancy) 8.5 Intraamniotic Infection (Chorioamnionitis) & Maternal Sepsis
10 Chapter 9: Postpartum Physiology & Immediate Recovery Care
9.1 Postpartum Physiologic Changes & Maternal Systemic Adaptations 9.2 Fourth Stage of Labor & Immediate Recovery Care 9.3 Routine Postpartum Nursing Assessment & Clinical Care (BUBBLE-HE) 9.4 Rh Isoimmunization, Alloimmunization & Postpartum Immunizations 9.5 Postpartum Discharge Teaching, Warning Signs & Maternal Safety
11 Chapter 10: Postpartum Adaptation, Hemorrhage & Clinical Complications
10.1 Postpartum Hemorrhage: Definition, Risk Stratification, 4 Ts, QBL & Pharmacotherapy 10.2 Postpartum Infections: Endometritis, Wound Infections, Sepsis & Postpartum Pyrexia 10.3 Thromboembolic Disorders: DVT, Pulmonary Embolism & Septic Pelvic Thrombophlebitis 10.4 Perinatal Mood & Anxiety Disorders: Postpartum Blues, PPD, Anxiety & Postpartum Psychosis 10.5 Lactation Physiology, Breastfeeding Complications, Engorgement & Medication Safety
12 Chapter 11: Newborn Care, Transition & Clinical Assessment
11.1 Neonatal Physiologic Transition & Cardiorespiratory Adaptation 11.2 Immediate Newborn Care, Apgar Scoring & Delivery Room Stabilization 11.3 Newborn Thermoregulation & Pathophysiology of Cold Stress 11.4 Gestational Age & Neonatal Growth Assessment 11.5 Comprehensive Newborn Head-to-Toe Examination & Normal Variants
13 Chapter 12: Newborn Complications, Resuscitation & High-Acuity Management
12.1 Neonatal Resuscitation Program (NRP 8th Edition) & Delivery Room Resuscitation 12.2 Neonatal Glucose Homeostasis, Hypoglycemia Screening & Clinical Management 12.3 Neonatal Hyperbilirubinemia, Bilirubin Metabolism & Phototherapy Protocols 12.4 Neonatal Respiratory Distress: TTN, RDS, Meconium Aspiration & Persistent Pulmonary Hypertension (PPHN) 12.5 Neonatal Sepsis, Congenital Infections & Neonatal Abstinence Syndrome (NAS/NOWS)
14 Chapter 13: Professional Practice, Legal-Ethical Frameworks, Patient Safety & Quality Improvement
13.1 Legal Aspects of Perinatal Nursing & High-Risk Documentation Standards 13.2 Ethical Principles in Perinatal Care & Maternal-Fetal Conflicts 13.3 Quality Improvement, Perinatal Safety Initiatives & AIM Bundles 13.4 Patient Safety Culture, Team Communication & Clinical Escalation 13.5 Evidence-Based Practice, Research Utilization & Perinatal Guidelines
12.3 Neonatal Hyperbilirubinemia, Bilirubin Metabolism & Phototherapy Protocols
Key Takeaways Explain This Topic AI
Bilirubin Conjugation & Pathologic Thresholds: Unconjugated bilirubin is lipophilic and neurotoxic until hepatic conjugation by UGT1A1 yields water-soluble conjugated bilirubin; jaundice appearing within the first 24 hours of life, rising >0.2 mg/dL/hr (>5 mg/dL/day), or direct bilirubin >1.0 mg/dL is pathologic by definition and warrants immediate evaluation.
Isoimmune Hemolytic Etiologies: Maternal IgG isoimmunization causes hemolytic disease: ABO incompatibility (maternal Type O with infant Type A or B; DAT positive/weakly positive) produces mild-to-moderate hemolysis; Rh (D) isoimmunization (Rh-negative mother, Rh-positive infant; DAT strongly positive) produces severe hemolysis, profound anemia, and hydrops fetalis.
Feeding-Related Jaundice Patterns: Breastfeeding Jaundice (suboptimal intake / lactation failure) develops at 2 to 4 days secondary to inadequate colostrum intake, dehydration (>8%–10% weight loss), and increased enterohepatic circulation; Breast Milk Jaundice develops at 4 to 7 days (peaking at 2 weeks) due to milk factors inhibiting UGT1A1 in thriving, well-hydrated infants.
Intensive Phototherapy Principles: Intensive phototherapy delivers narrow-spectrum blue LED light (460–490 nm, irradiance ≥30 μW/cm²/nm) to convert unconjugated bilirubin into lumirubin via irreversible structural photoisomerization; essential safeguards include continuous opaque eye shielding (removed for feeds), maximum skin exposure, thermoregulation, and turning lights off during blood sampling.
Acute Bilirubin Encephalopathy (ABE) & Kernicterus: ABE manifests with lethargy and poor feeding progressing to retrocollis, opisthotonos, and high-pitched crying, requiring emergent double-volume exchange transfusion (160–180 mL/kg); untreated ABE causes irreversible Kernicterus Spectrum Disorder (choreoathetoid cerebral palsy, sensorineural deafness, upward gaze palsy).
Last updated: August 2026
Bilirubin Synthesis, Hepatic Conjugation & Enterohepatic Recirculation
Neonatal hyperbilirubinemia is one of the most frequent clinical conditions encountered in inpatient obstetric and newborn units, affecting over 60% of term and 80% of preterm infants during the first week of life. While mild unconjugated hyperbilirubinemia is a benign transitional phenomenon, severe unmonitored hyperbilirubinemia carries the devastating risk of Bilirubin-Induced Neurologic Dysfunction (BIND) and permanent Kernicterus Spectrum Disorder . +---------------------------------------------------------------------------------------------------+
- | BILIRUBIN BIOCHEMICAL PATHWAY IN THE NEONATE |
- +---------------------------------------------------------------------------------------------------+
[ 1. HEME BREAKDOWN & RETICULOENDOTHELIAL CATABOLISM ]
- Neonatal RBC Lifespan: 70-90 days (vs 120 days in adults) + High RBC Mass (Hct 50-60%).
- Senescent RBCs broken down by Heme Oxygenase ──▶ Biliverdin.
- Biliverdin converted by Biliverdin Reductase ──▶ Unconjugated (Indirect) Bilirubin.
- │
- ▼
- [ 2. SYSTEMIC CIRCULATION & ALBUMIN BINDING ]
- Unconjugated Bilirubin is LIPID-SOLUBLE, NON-POLAR, and POTENTIALLY NEUROTOXIC.
- Binds reversibly to plasma Albumin for transport to the liver.
- Free (unbound) bilirubin can cross the blood-brain barrier into basal ganglia.
- │
- ▼
- [ 3. HEPATIC UPTAKE & CONJUGATION ]
- Hepatocyte uptake via Y- and Z-carrier proteins (Ligandins).
- Hepatic enzyme: Uridine Diphosphoglucuronosyl Transferase (UGT1A1).
- Attaches glucuronic acid ──▶ Conjugated (Direct) Bilirubin (WATER-SOLUBLE, Non-toxic).
- │
- ▼
- [ 4. BILIARY EXCRETION & ENTEROHEPATIC CIRCULATION ]
- Conjugated bilirubin excreted into bile ducts ──▶ Duodenum / Intestinal lumen.
- In Adults: Intestinal flora reduces conjugated bilirubin to Urobilinogen / Stercobilin (stool).
- In Neonates: Sterile intestine lacks flora; mucosal enzyme BETA-GLUCURONIDASE deconjugates
- direct bilirubin back into unconjugated bilirubin, which is REABSORBED into portal blood
(Enterohepatic Recirculation).
Why Neonates are Physiologically Predisposed to Jaundice
Accelerated Heme Production: Neonates produce bilirubin at more than twice the adult rate ( 8.5 mg/kg/day 8.5\text{ mg/kg/day} 8.5 mg/kg/day vs 3.8 mg/kg/day 3.8\text{ mg/kg/day} 3.8 mg/kg/day ) due to higher circulating red cell volume and shortened red cell lifespan.
Immature Hepatic Conjugation: Hepatic UGT1A1 enzyme activity at birth is only 1% of adult levels, reaching adult maturity only by 6 to 14 weeks of age.
Exaggerated Enterohepatic Recirculation: High concentrations of intestinal beta-glucuronidase , combined with delayed meconium evacuation and sterile bowel, cause substantial deconjugation and enterohepatic reabsorption of bilirubin.
Differential Diagnosis: Physiologic vs. Pathologic Jaundice
Clinical jaundice progresses in a cephalocaudal pattern (starting on the face, advancing to the chest, abdomen, extremities, and finally palms/soles) as total serum bilirubin (TSB) levels rise. Visual estimation of bilirubin depth is notoriously unreliable across diverse skin tones and must always be confirmed with Transcutaneous Bilirubin (TcB) or Total Serum Bilirubin (TSB) measurement. +---------------------------------------------------------------------------------------------------+
- | CRITERIA DEFINING PATHOLOGIC JAUNDICE |
- | (ANY of the following mandates urgent workup) |
- +---------------------------------------------------------------------------------------------------+
1. Clinical jaundice visible within the first 24 hours of life.
2. Total Serum Bilirubin (TSB) rising at a rate >0.2 mg/dL/hour (or >5.0 mg/dL/24 hours).
3. TSB exceeding the hour-specific phototherapy threshold on the 2022 AAP Hyperbilirubinemia Nomogram.
4. Conjugated (Direct) Bilirubin >1.0 mg/dL (suggesting neonatal cholestasis or biliary atresia).
5. Jaundice persisting beyond 14 days of life in term infants (or >21 days in preterm infants).
- +---------------------------------------------------------------------------------------------------+
- Comparative Matrix: Physiologic vs. Pathologic Jaundice
Clinical Parameter Physiologic Jaundice Pathologic Jaundice
Onset Timeline Appears after 24 hours of life (peaks days 3–5 in term, days 5–7 in preterm). Appears within first 24 hours of life.
Peak TSB Level Term: 5 to 6 mg/dL (rarely >12 mg/dL); Preterm: 10 to 12 mg/dL. Exceeds AAP phototherapy cutoff for gestational age and hours of life.
Rate of TSB Rise < 0.2 mg/dL/hr <0.2\text{ mg/dL/hr} < 0.2 mg/dL/hr ( < 5 mg/dL/day <5\text{ mg/dL/day} < 5 mg/dL/day ). > 0.2 mg/dL/hr >0.2\text{ mg/dL/hr} > 0.2 mg/dL/hr ( > 5 mg/dL/day >5\text{ mg/dL/day} > 5 mg/dL/day ).
Direct Bilirubin Normal ( < 1.0 mg/dL <1.0\text{ mg/dL} < 1.0 mg/dL ). May be elevated ( > 1.0 mg/dL >1.0\text{ mg/dL} > 1.0 mg/dL or > 20 % >20\% > 20% of TSB).
Etiology Immature UGT1A1 enzyme, high RBC turnover, enterohepatic circulation. Isoimmune hemolysis (ABO, Rh), RBC enzymopathies (G6PD), sepsis, cephalohematoma.
Clinical Management Supportive; promote frequent enteral feeds, monitor TcB/TSB progression. Intensive phototherapy, IVIG, double-volume exchange transfusion.
Breastfeeding Jaundice vs. Breast Milk Jaundice +---------------------------------------------------------------------------------------------------+
- | DIFFERENTIATING BREASTFEEDING VS. BREAST MILK JAUNDICE |
- +---------------------------------------------------------------------------------------------------+
- ┌───────────────────────────────────┬───────────────────────────────────┐
- │ BREASTFEEDING JAUNDICE │ BREAST MILK JAUNDICE │
- │ (Lactation Failure / Intake Deficit)│ (Human Milk Inhibitor Effect) │
- ├───────────────────────────────────┼───────────────────────────────────┤
- │ • Onset: Days 2 to 4 of life │ • Onset: Days 4 to 7; peaks 2 wk │
- │ • Mechanism: Inadequate caloric │ • Mechanism: Factors in human │
- │ intake, poor latch, delayed │ milk (beta-glucuronidase, free │
- │ meconium clearance -> exaggerated│ fatty acids) inhibit UGT1A1. │
- │ enterohepatic recirculation. │ │
- │ • Clinical State: Dehydration, │ • Clinical State: Thriving, alert,│
- │ weight loss >8-10%, oliguria, │ vigorous infant, gaining weight,│
- │ infrequent meconium stools. │ normal urine/stool output. │
- │ • Treatment: Lactation support, │ • Treatment: Reassure parents, │
- │ feed q2-3h (10-12x/day), donor │ CONTINUE BREASTFEEDING, photo- │
- │ milk/formula supplementation PRN│ therapy if AAP threshold met. │
- └───────────────────────────────────┴───────────────────────────────────┘
- Isoimmune Hemolytic Disease: ABO Incompatibility & Rh Isoimmunization
Isoimmune hemolytic disease occurs when maternal alloantibodies cross the placenta and destroy fetal/neonatal erythrocytes expressing foreign paternal antigens.
1. ABO Incompatibility
Epidemiology: Most common cause of isoimmune hemolytic disease (~15–20% of pregnancies; clinically significant hemolysis in 20% of those).
Prerequisites: Mother is Blood Type O ; Infant is Blood Type A or Blood Type B .
Pathophysiology: Individuals with Type O blood naturally possess IgG anti-A and anti-B antibodies (unlike Type A or B individuals whose isohemagglutinins are predominantly IgM and cannot cross the placenta). These maternal IgG antibodies cross the placenta into fetal circulation, binding to A or B antigens on neonatal red blood cells.
Clinical Presentation: Can occur during the first pregnancy without prior sensitization. Causes mild-to-moderate jaundice starting in the first 24 hours of life. Direct Antiglobulin Test (DAT / Direct Coombs) is positive or weakly positive. Blood smear reveals microspherocytes.
2. Rh (D) Isoimmunization
Prerequisites: Mother is Rh-negative (d/d) ; Infant is Rh-positive (D/d or D/D) .
Pathophysiology: Sensitization occurs when fetal Rh-positive red cells enter maternal circulation during delivery, miscarriage, amniocentesis, or placental abruption. In subsequent Rh-positive pregnancies, maternal anti-D IgG antibodies vigorously cross the placenta, causing profound extravascular and intravascular hemolysis.
Clinical Presentation: Severe, rapid hemolysis. DAT is strongly positive . Severe anemia at birth, prominent hepatosplenomegaly (extramedullary hematopoiesis), rapid TSB rise ( > 0.5 mg/dL/hr >0.5\text{ mg/dL/hr} > 0.5 mg/dL/hr ), and severe Erythroblastosis Fetalis / Hydrops Fetalis (anasarca, pericardial/pleural effusions, high-output cardiac failure, intrauterine demise).
Phototherapy Bio-Mechanisms & Clinical Nursing Care Bundles
Phototherapy transforms unconjugated bilirubin into water-soluble photoisomers that can be excreted in bile and urine without requiring hepatic glucuronidation. +---------------------------------------------------------------------------------------------------+
- | PHOTOTHERAPY BIOCHEMICAL MECHANISMS |
- +---------------------------------------------------------------------------------------------------+
- Photochemical Reaction Biochemical Process & Clinical Significance
- --------------------------- ---------------------------------------------------------------------
1. Structural Isomerization IRREVERSIBLE conversion of (4Z,15Z)-bilirubin to LUMIRUBIN.
(Primary Pathway) Lumirubin is highly water-soluble, non-neurotoxic, and rapidly excreted
in bile and urine. Responsible for 80% of phototherapy clearance.
---------------------------------------------------------------------------------------------------
2. Configurational REVERSIBLE conversion of (4Z,15Z)-bilirubin to (4Z,15E)-bilirubin.
Isomerization Excreted in bile but can re-isomerize back to toxic 4Z,15Z form in bowel.
- --------------------------------------------------------------------------------------------------
- 3. Photo-oxidation Minor pathway breaking bilirubin down into small polar, colorless pyrroles
excreted exclusively in urine.
- +---------------------------------------------------------------------------------------------------+
- Comprehensive Phototherapy Nursing Care Bundle
Optical Spectrum & Irradiance: Narrow-band blue LED light in the 460 to 490 nm wavelength delivering intensive irradiance ≥ 30 μ W/cm 2 /nm \ge 30\text{ }\mu\text{W/cm}^2\text{/nm} ≥ 30 μ W/cm 2 /nm . Position lights at manufacturer-specified distance to maximize irradiance.
Maximum Surface Area Exposure: Strip infant to diaper only; fold diaper waist low to expose maximum skin. Utilize fiberoptic pads (BiliBlanket) under the infant combined with overhead LED banks ("double or triple phototherapy").
Opaque Eye Protection: Apply dedicated, properly sized opaque eye patches over closed eyes to prevent retinal photochemical injury. Remove eye patches during parental feedings to assess for conjunctivitis, corneal abrasion, and facilitate maternal-infant bonding.
Thermoregulation: Monitor axillary temperature every 2 to 4 hours; risk of hyperthermia (overhead lights) or hypothermia (undressed state).
Hydration & Stool Assessment: Promote enteral feeding every 2 to 3 hours. Bilirubin is primarily excreted via stool; loose, dark greenish-brown stools are expected. Monitor diaper counts and urine specific gravity. Routine IV fluid supplementation is not recommended unless signs of dehydration or impending exchange transfusion are present.
TSB Blood Sampling Safeguard: Turn off the overhead phototherapy lights while drawing capillary or venous blood for TSB to prevent photo-degradation of bilirubin inside the collection tube.
Bronze Baby Syndrome: A benign, transient dark gray-brown skin, serum, and urine discoloration occurring when phototherapy is administered to infants with elevated direct (conjugated) bilirubin (cholestasis) , caused by photo-induced polymer accumulation of copper-porphyrin complexes. Promptly investigate underlying hepatic or biliary pathology.
Acute Bilirubin Encephalopathy (ABE) & Kernicterus Spectrum Disorders
Unconjugated, free (unbound) bilirubin is highly lipophilic and readily crosses the blood-brain barrier. It deposits preferentially in lipid-rich central nervous system structures: the basal ganglia (globus pallidus), subthalamic nuclei, hippocampus, oculomotor nuclei, and auditory brainstem pathways (cranial nerve VIII) . +---------------------------------------------------------------------------------------------------+
- | PROGRESSION OF BILIRUBIN NEUROTOXICITY |
- +---------------------------------------------------------------------------------------------------+
[ 1. ACUTE BILIRUBIN ENCEPHALOPATHY (ABE) - ACUTE PHASE ]
• EARLY PHASE (Reversible with rapid intervention):
Lethargy, hypotonia, mild stupor, poor suck, weak high-pitched cry.
• INTERMEDIATE PHASE (Borderline reversibility):
Moderate stupor, irritability, hypertonia, RETROCOLLIS (arching of neck backwards),
OPISTHOTONOS (arching of back/spine backwards), shrill piercing cry, fever.
• ADVANCED PHASE (Irreversible neuronal necrosis):
Pronounced retrocollis and opisthotonos, bicycling movements, intractable seizures, apnea,
inability to feed, coma, respiratory arrest (50% mortality).
- │
- ▼ (Surviving Infants)
- [ 2. KERNICTERUS SPECTRUM DISORDER (KSD) - CHRONIC PERMANENT SEQUELAE ]
- Choreoathetoid Cerebral Palsy (Severe extrapyramidal movement disorder, involuntary chorea).
- Sensorineural Hearing Loss / Auditory Neuropathy Spectrum Disorder (Damage to CN VIII).
- Upward Gaze Palsy / Parinaud Syndrome (Impaired vertical saccadic eye movements).
- Dental Enamel Hypoplasia & Yellow-Green Staining of deciduous teeth.
Exchange Transfusion Protocols & IVIG Therapy
When intensive phototherapy fails to arrest a rapid TSB rise, or when TSB reaches the AAP exchange transfusion threshold, emergent procedural and pharmacologic interventions must be executed.
1. Intravenous Immune Globulin (IVIG)
Indication: Isoimmune hemolytic disease (Rh or ABO incompatibility) when TSB continues to rise despite intensive phototherapy or is within 2 to 3 mg/dL of the exchange transfusion threshold.
Dose & Mechanism: 0.5 to 1.0 g/kg IV infused over 2 hours (may repeat in 12 hours). IVIG blocks Fc receptors on neonatal reticuloendothelial macrophages, preventing the clearance and destruction of antibody-coated red blood cells.
2. Double-Volume Exchange Transfusion (DVET)
Indication: TSB at or above the exchange threshold, or any infant exhibiting intermediate-to-advanced signs of Acute Bilirubin Encephalopathy (retrocollis, opisthotonos).
Mechanism: Replaces approximately 85% to 90% of circulating red blood cells and reduces total serum bilirubin concentration by 50%.
Volume Calculation: Double-Volume = 2 × Neonatal Blood Volume ( 80 – 90 mL/kg ) = 160 – 180 mL/kg \text{Double-Volume} = 2 \times \text{Neonatal Blood Volume} (80\text{--}90\text{ mL/kg}) = \mathbf{160\text{--}180\text{ mL/kg}} Double-Volume = 2 × Neonatal Blood Volume ( 80 – 90 mL/kg ) = 160 – 180 mL/kg .
Blood Product: Fresh (<5 days old), irradiated, CMV-negative, leukoreduced Type O-negative Packed Red Blood Cells reconstituted with AB plasma , crossmatched against maternal serum.
Nursing Surveillance: Continuous cardiorespiratory and arterial line monitoring; perform exchange in small aliquots (5 mL/kg over 2–4 minutes); monitor for hypocalcemia (citrate in preservative binds calcium; administer 10% calcium gluconate per protocol) and rebound hypoglycemia.